Poolbeg Pharma
Spun out of hVIVO plc (formerly Open Orphan plc) in 2021, we have access to over 20 years knowledge, expertise, and clinical data from hVIVO.We are led by a team with proven capabilities in identifying, acquiring, and accelerating assets through development to commercialisation.sing innovative technologies, we are developing a range of products to address diseases with a high unmet medical need.
We aim to rapidly generate early human efficacy data and then partner / out-licence our products to pharma & biotech companies for further development.
Carol Dalton
Co-founder & VP Investor Relations & Public Relations
Ian O'Connell
CFO
Pracipio
Better valuation of development and software investments can give you a tax-advantage - Bespoke developments don't always deliver on budget and schedule. Revaluation in line with market and utility values can realize immediate and long terms value.
Fredrik Elg
Director
PrecisionLife
diseases, including CNS, autoimmune, cardiovascular, respiratory, and metabolic diseases. We have
multiple strategic R&D collaborations with biopharma partners and have generated deep disease insights in
over 50 indications.
We map novel targets to specific patient subgroups with causal genetic and mechanistic explanations and
disease prevalence. The patient stratification biomarkers (PSBs) that we generate are unique, patentable IP
that capture mechanistic insights into the mapping of causative disease biology to patient subgroups.
These biomarkers help design smaller, faster, more targeted clinical trials and to build highly predictive
complementary diagnostics. We also work with biopharma companies to reevaluate clinical trial results,
identify secondary indications and out-licensing opportunities for pipeline and/or stalled assets - informing
and de-risking every stage of drug discovery and clinical development, from concept to clinic.
Rowan Gardner
Chief Business & Investment Officer
Gianluca Valenza
Business Development Director
